Table 2.
Ocular MMP-9 status by study group.
Preservative-free treatment (tafluprost) (n=30) | BAK-containing treatment (latanoprost) (n=30) | Untreated (control) (n=30) | |
---|---|---|---|
MMP-9 (>40 ng/mL) | |||
Negative | 25 eyes (83.3%) | 16 eyes (53.3%) | 25 eyes (83.3%) |
Positive∗ | 5 eyes (16.7%∗,‡) | 14 eyes (46.7%) | 5 eyes (16.7%∗,‡) |
Level of significance: ∗p < 0.05; ‡significance of difference relative to the BAK-containing treatment (latanoprost) group.